Supplements and Nutraceuticals

“First, do no harm. Second, be honest about what we don’t know.” This chapter reviews supplements and nutraceuticals commonly used in ME/CFS. We emphasize accessible, over-the-counter options that patients can try without prescription, while being honest about the limited evidence base. Most supplements have not been rigorously tested in ME/CFS-specific trials; recommendations are based on mechanism, related-condition evidence, and patient-reported outcomes.

Very few supplements have been tested in randomized controlled trials specifically for ME/CFS. Most evidence comes from: (1) mechanistic plausibility based on documented ME/CFS abnormalities, (2) trials in related conditions (fibromyalgia, Long COVID, chronic fatigue), (3) small open-label studies, and (4) patient surveys. We note the evidence level for each supplement. “Widely used” does not mean “proven effective.”

WarningLimitation: Supplement Evidence: Mechanism-Based Reasoning, Not Clinical Proof

Despite widespread use and biological plausibility, the supplement recommendations in this chapter face a fundamental evidence gap:

  • Fewer than five supplements discussed here have been tested in randomized placebo-controlled trials specifically in ME/CFS—notably NADH (Forsyth et al. 1999) and CoQ10+NADH (Castro-Marrero et al. 2021). Acetyl-L-carnitine has been studied in a randomized (open-label) ME/CFS trial (Vermeulen and Scholte 2004) but without a placebo arm. Most evidence for other supplements derives from mechanistic reasoning, related-condition trials, or patient surveys with inherent reporting bias.
  • The observation that “widely used” supplements dominate patient community recommendations does not constitute efficacy evidence; popular adoption may reflect hope, accessibility, and social transmission rather than therapeutic benefit.
  • Combination protocols (e.g., CoQ10 + L-carnitine + D-ribose) are recommended based on complementary biochemical rationale, but potential interactions, optimal ratios, and combined efficacy have not been studied.
  • Supplement quality, bioavailability, and dose-response relationships vary substantially between brands and formulations—factors not addressed by the general dosing ranges provided.
NoteChapter Roadmap: How to Use This Chapter

For patients: start with the foundational electrolytes and hydration section (Foundational Supplements: Electrolytes and Hydration) — often the single most impactful step — then the mitochondrial and energy-support section (Mitochondrial and Energy Support) for the best-evidenced supplements; read the HIT-safe electrolyte notes if you have mast-cell or histamine sensitivity.

For caregivers: use the electrolytes section to prepare a safe DIY oral-rehydration solution, and the energy-support section to help the patient budget supplement costs against the evidence.

For clinicians: read the combination guide within Mitochondrial and Energy Support for evidence-based pairing (e.g., CoQ10 + NADH) and the drug-interaction warnings; note each supplement’s evidence level before recommending.

For researchers: read the limitation block first — fewer than five supplements have ME/CFS-specific RCTs; the chapter maps the mechanism-based reasoning and related-condition evidence that needs ME/CFS-specific validation.

1 Contents

References

Castro-Marrero, Jesús, María José Segundo, Mónica Lacasa, Albert Martinez-Martinez, Ramon Sanmartín Sentañes, and José Alegre-Martin. 2021. “Effect of Dietary Coenzyme Q\(_{10}\) Plus NADH Supplementation on Fatigue Perception and Health-Related Quality of Life in Individuals with Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: A Prospective, Randomized, Double-Blind, Placebo-Controlled Trial.” Nutrients 13 (8): 2658. https://doi.org/10.3390/nu13082658.
Forsyth, L M, H G Preuss, A L MacDowell, L Chiazze, G D Birkmayer, and J A Bellanti. 1999. “Therapeutic Effects of Oral NADH on the Symptoms of Patients with Chronic Fatigue Syndrome.” Annals of Allergy, Asthma & Immunology 82 (2): 185–91. https://doi.org/10.1016/S1081-1206(10)62595-1.
Vermeulen, Ruud C W, and Hans R Scholte. 2004. “Exploratory Open Label, Randomized Study of Acetyl- and Propionylcarnitine in Chronic Fatigue Syndrome.” Psychosomatic Medicine 66 (2): 276–82. https://doi.org/10.1097/01.psy.0000116249.60477.e9.